In the claims:

1. Cancelled

2. (Currently amended) The compound ~~according to Claim 1~~, or a pharmaceutically acceptable salt or stereoisomer thereof, of the Formula II:



II

wherein

a is 0 or 1;

b is 0 or 1;

m is 0, 1 or 2;

r is 0 or 1;

s is 0 or 1;

~~a, b, r, s, R^4, R^5, R^6 and R^7 are defined as in Claim 1 for the compound of the Formula I and~~

p' is 0 to 2;

R^2 is selected from:

1) $(C=O)_aC_1$-C_{10} alkyl,
2) $(C=O)_a$aryl,
3) $(C=O)_aNR^6R^7$,
4) $(C=O)_aC_3$-C_8 cycloalkyl,
5) $(C=O)_a$heterocyclyl,
6) $SO_2NR^6R^7$, and
7) SO_2C_1-C_{10} alkyl,

said alkyl, aryl, cycloalkyl, and heterocyclyl is optionally substituted with one or more substituents selected from R^4;

R^{2a} is selected from: halogen and $(C_1\text{-}C_6)$alkyl;

R^{3a} and R^{3b} are independently selected from: hydrogen, $(C_1\text{-}C_6)$alkyl, trifluoromethyl and halogen; and

R^{4a} and R^{4b} are independently selected from: hydrogen, halogen and $(C_1\text{-}C_6)$alkyl, provided that at lease one is not hydrogen, or

R^{4a} and R^{4b} are combined to form a diradical selected from $-CH_2CH_2CH_2CH_2-$, $-CH_2CH_2CH_2-$, –CH=CH-O- and –CH=CH-N-

R^4 is independently selected from:

1) $(C=O)_aO_bC_1\text{-}C_{10}$ alkyl,
2) $(C=O)_aO_b$aryl,
3) $C_2\text{-}C_{10}$ alkenyl,
4) $C_2\text{-}C_{10}$ alkynyl,
5) $(C=O)_aO_b$ heterocyclyl,
6) CO_2H,
7) halo,
8) CN,
9) OH,
10) $O_bC_1\text{-}C_6$ perfluoroalkyl,
11) $O_a(C=O)_bNR^6R^7$,
12) oxo,
13) CHO,
14) $(N=O)R^6R^7$,
15) $(C=O)_aO_bC_3\text{-}C_8$ cycloalkyl,
16) $SO_2NR^6R^7$, and
17) $SO_2C_1\text{-}C_{10}$ alkyl,

said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one or more substituents selected from R^5;

R^5 is selected from:

1) $(C=O)_rO_s(C_1\text{-}C_{10})$alkyl,

2) $O_r(C_1\text{-}C_3)$perfluoroalkyl,
3) $(C_0\text{-}C_6)$alkylene-$S(O)_mR^a$,
4) oxo,
5) OH,
6) halo,
7) CN,
8) $(C{=}O)_rO_s(C_2\text{-}C_{10})$alkenyl,
9) $(C{=}O)_rO_s(C_2\text{-}C_{10})$alkynyl,
10) $(C{=}O)_rO_s(C_3\text{-}C_6)$cycloalkyl,
11) $(C{=}O)_rO_s(C_0\text{-}C_6)$alkylene-aryl,
12) $(C{=}O)_rO_s(C_0\text{-}C_6)$alkylene-heterocyclyl,
13) $(C{=}O)_rO_s(C_0\text{-}C_6)$alkylene-$N(R^b)_2$,
14) $C(O)R^a$,
15) $(C_0\text{-}C_6)$alkylene-CO_2R^a,
16) C(O)H,
17) $(C_0\text{-}C_6)$alkylene-CO_2H, and
18) $C(O)N(R^b)_2$,

said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heterocyclyl is optionally substituted with up to three substituents selected from R^b, OH, $(C_1\text{-}C_6)$alkoxy, halogen, CO_2H, CN, $O(C{=}O)C_1\text{-}C_6$ alkyl, oxo, and $N(R^b)_2$;

R^6 and R^7 are independently selected from:

1) H,
2) $(C{=}O)O_bC_1\text{-}C_{10}$ alkyl,
3) $(C{=}O)O_bC_3\text{-}C_8$ cycloalkyl,
4) $(C{=}O)O_b$aryl,
5) $(C{=}O)O_b$heterocyclyl,
6) $C_1\text{-}C_{10}$ alkyl,
7) aryl,
8) $C_2\text{-}C_{10}$ alkenyl,
9) $C_2\text{-}C_{10}$ alkynyl,
10) heterocyclyl,
11) $C_3\text{-}C_8$ cycloalkyl,
12) SO_2R^a, and
13) $(C{=}O)NR^b{}_2$,

said alkyl, cycloalkyl, aryl, heterocylyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R^6, or

R^6 and R^7 can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 4-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one or more substituents selected from R^5;

R^a is $(C_1\text{-}C_6)$alkyl, $(C_3\text{-}C_6)$cycloalkyl, aryl, or heterocyclyl; and

R^b is H, $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkyl-NR^a_2, $(C_1\text{-}C_6)$alkyl-NH_2, $(C_1\text{-}C_6)$alkyl-NHR^a, aryl, heterocyclyl, $(C_3\text{-}C_6)$cycloalkyl, $(C{=}O)OC_1\text{-}C_6$ alkyl, $(C{=}O)C_1\text{-}C_6$ alkyl or $S(O)_2R^a$.

3. (Original) The compound according to Claim 2 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

wherein:

p' is 0 to 2;
r is 0 or 1;
s is 0 or 1;

R^2 is $(C_1\text{-}C_6)$alkylene-NR^6R^7; said alkylene is optionally substituted with up to three substituents selected from OH, $(C_1\text{-}C_6)$alkoxy, halogen, CO_2H, CN, $O(C{=}O)C_1\text{-}C_6$ alkyl, oxo, and NR^6R^7;

R^{2a} is selected from: halogen and $(C_1\text{-}C_6)$alkyl;

R^{3a} and R^{3b} are independently selected from: hydrogen, $(C_1\text{-}C_6)$alkyl, trifluoromethyl and halogen;

R^{4a} and R^{4b} are independently selected from: hydrogen, halogen and $(C_1\text{-}C_6)$alkyl, provided that at least one is not hydrogen;

R^5 is selected from:

1) $(C=O)_rO_s(C_1\text{-}C_{10})$alkyl,
2) $O_r(C_1\text{-}C_3)$perfluoroalkyl,
3) $(C_0\text{-}C_6)$alkylene-$S(O)_mR^a$,
4) oxo,
5) OH,
6) halo,
7) CN,
8) $(C=O)_rO_s(C_2\text{-}C_{10})$alkenyl,
9) $(C=O)_rO_s(C_2\text{-}C_{10})$alkynyl,
10) $(C=O)_rO_s(C_3\text{-}C_6)$cycloalkyl,
11) $(C=O)_rO_s(C_0\text{-}C_6)$alkylene-aryl,
12) $(C=O)_rO_s(C_0\text{-}C_6)$alkylene-heterocyclyl,
13) $(C=O)_rO_s(C_0\text{-}C_6)$alkylene-$N(R^b)_2$,
14) $C(O)R^a$,
15) $(C_0\text{-}C_6)$alkylene-CO_2R^a,
16) C(O)H,
17) $(C_0\text{-}C_6)$alkylene-CO_2H, and
18) $C(O)N(R^b)_2$,

said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heterocyclyl is optionally substituted with up to three substituents selected from R^b, OH, $(C_1\text{-}C_6)$alkoxy, halogen, CO_2H, CN, $O(C=O)C_1\text{-}C_6$ alkyl, oxo, and $N(R^b)_2$;

R^6 and R^7 are independently selected from:

1) H,
2) $C_1\text{-}C_{10}$ alkyl,
3) aryl,
4) heterocyclyl,
5) $C_2\text{-}C_{10}$ alkenyl,
6) $C_2\text{-}C_{10}$ alkynyl, and
7) $C_3\text{-}C_8$ cycloalkyl,

said alkyl, cycloalkyl, aryl, heterocylyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R^5, or

R^6 and R^7 can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 4-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one or more substituents selected from R^5;

R^a is $(C_1\text{-}C_6)$alkyl, $(C_3\text{-}C_6)$cycloalkyl, aryl, or heterocyclyl; and

R^b is H, $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkyl-NR^a_2, $(C_1\text{-}C_6)$alkyl-NH_2, $(C_1\text{-}C_6)$alkyl-NHR^a, aryl, heterocyclyl, $(C_3\text{-}C_6)$cycloalkyl, $(C{=}O)OC_1\text{-}C_6$ alkyl, $(C{=}O)C_1\text{-}C_6$ alkyl or $S(O)_2R^a$.

4. (Original) A compound which is

2-(2-bromophenyl)-3-(3-fluoro-4-methylphenyl)pyrimidin-4(3H)-one.

5. (Currently amended) A pharmaceutical composition that is comprised of a compound in accordance with Claim ~~1~~ 2 and a pharmaceutically acceptable carrier.

6. (Original) A pharmaceutical composition that is comprised of a compound in accordance with Claim 3 and a pharmaceutically acceptable carrier.

7. Cancelled

8. Previously cancelled

9. Cancelled

10.- 19. Previously cancelled

20.-23. Cancelled

24.-26. Previously cancelled

27.-33. Cancelled